Vielot Nadja A, Lane Robyn M, Loefstedt Kaitlyn, Cunningham Jennifer L, Everson Jason, Tiller Eli, Johnson Patel Sarah E, Smith Jennifer S
Department of Family Medicine, University of North Carolina at Chapel Hill, 590 Manning Drive, Chapel Hill, North Carolina, 27599, USA.
Department of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Pilot Feasibility Stud. 2023 Aug 31;9(1):153. doi: 10.1186/s40814-023-01379-y.
While 9-valent human papillomavirus (HPV) vaccination is approved by the US Food and Drug Administration for use in adolescents as young as age 9, providers typically recommend it at ages 11-12. Studies suggest that recommending HPV vaccination at 9 or 10 years of age could increase up-to-date vaccination by age 13, which could especially benefit rural populations with reduced access to primary health care and lower HPV vaccination coverage than urban areas. This study aimed to assess the feasibility of the age-9 recommendation of HPV vaccination in rural clinics. We conducted in-depth interviews with providers and staff from two primary care clinics in central North Carolina to understand attitudes toward recommending HPV vaccination to 9- and 10-year-olds. All interviewees agreed that HPV vaccination was important for cancer prevention and should be recommended before the onset of sexual activity, agreeing that HPV vaccination could be initiated before age 11 to improve timeliness and completion of the vaccination series. However, opinions were mixed on whether HPV vaccination should be initiated as young as 9 years old. Two key informants recruited from two university-affiliated clinics described their experiences recommending HPV vaccination to 9- and 10-year-olds, including a modified vaccination schedule that promotes HPV vaccination during routine well-child visits, prior to pubertal onset, and alongside other recommended adolescent vaccines. Age-9 recommendation and administration of HPV vaccination is possible with minimal changes to current clinical practices and could increase the convenience and acceptability of HPV vaccination in under-vaccinated settings.
虽然九价人乳头瘤病毒（HPV）疫苗已获美国食品药品监督管理局批准，可用于9岁及以上的青少年，但医疗服务提供者通常建议在11至12岁接种。研究表明，建议9岁或10岁接种HPV疫苗可能会提高13岁时的疫苗接种率，这对那些获得初级医疗保健机会较少、HPV疫苗接种率低于城市地区的农村人口尤其有益。本研究旨在评估在农村诊所建议9岁接种HPV疫苗的可行性。我们对北卡罗来纳州中部两家初级保健诊所的医疗服务提供者和工作人员进行了深入访谈，以了解他们对向9岁和10岁儿童建议接种HPV疫苗的态度。所有受访者都认为HPV疫苗对预防癌症很重要，应该在开始性行为之前接种，他们一致认为可以在11岁之前开始接种HPV疫苗，以提高疫苗接种系列的及时性和完成率。然而，对于是否应在9岁就开始接种HPV疫苗，意见不一。从两家大学附属医院诊所招募的两名关键信息提供者描述了他们向9岁和10岁儿童建议接种HPV疫苗的经历，包括一种改进的疫苗接种时间表，即在常规儿童健康检查期间、青春期开始之前以及与其他推荐的青少年疫苗一起推广HPV疫苗接种。在对当前临床实践进行最小改变的情况下，9岁建议接种和接种HPV疫苗是可行的，并且可以提高疫苗接种率较低地区HPV疫苗接种的便利性和可接受性。
